Acknowledgement
이 논문은 2023년도 한의기반융합기술개발사업의 지원을 받아 수행된 다빈도 난치성 천식 협진치료 연구(No. HI20C120501)의 지원을 받아 수행된 과제입니다.
References
- Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect 2022;28(5):657-66. https://doi.org/10.1016/j.cmi.2022.01.014
- Kim YJ. COVID-19 and Long-Term Sequelae. The Korean Journal of Medicine 2022;97(1):23-7. https://doi.org/10.3904/kjm.2022.97.1.23
- Ambardar SR, Hightower SL, Huprikar NA, Chung KK, Singhal A, Collen JF. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic. J Clin Med 2021;10(11):2452.
- Michalski JE, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?. Transl Res 2022;241:13-24. https://doi.org/10.1016/j.trsl.2021.09.001
- Patrucco F, Solidoro P, Gavelli F, Apostolo D, Bellan M. Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks. Microorganisms 2023;11(4):895.
- Mohammadi A, Balan I, Yadav S, Matos WF, Kharawala A, Gaddam M, et al. Post-COVID-19 Pulmonary Fibrosis. Cureus 2022;14(3):e22770.
- Saiphoklang N, Patanayindee P, Ruchiwit P. The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study. Critical Care Research and Practice 2022;2022:9972846.
- Farghaly S, Badedi M, Ibrahim R, Sadhan MH, Alamoudi A, Alnami A, et al. Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study. Medicine (Baltimore) 2022;101(3):e28639.
- Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 2017;26(146):170057.
- Lu ZH, Yang CL, Yang GG, Pan WX, Tian LG, Zheng JX, et al. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial. Infect Dis Poverty 2021;10(1):31.
- Rumende CM, Susanto EC, Sitorus TP. The Management of Pulmonary Fibrosis in COVID-19. Acta Med Indones 2021;53(2):233-41.
- Hama Amin BJ, Kakamad FH, Ahmed GS, Ahmed SF, Abdulla BA, Mohammed SH, et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Ann Med Surg (Lond) 2022;77:103590.
- Kim YJ, Kim SE, Kim T, Yoon KW, Lee SH, Lee EJ, et al. Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID. Infect Chemother 2022;54(3):566-97. https://doi.org/10.3947/ic.2022.0141
- 전국한의과대학본초학교실. 본초학. 서울: 영림사; 2004, p. 154-6.
- Ahn J, Joo H, Park J, Park JW, Kim KI, Jung HJ, et al. The Effects of Lung-moistening Herbal Medicines on Bleomycin-induced Pulmonary Fibrosis Mouse Model. Processes 2020;8(1):102.
- Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 2006;3(11):e442.
- Spinou A, Birring SS. An update on measurement and monitoring of cough: what are the important study endpoints? J Thorac Dis 2014;6(Suppl 7):S728-34.
- Kim JW, Lee MY. Validity Evidences of VAS Pain Scale Utilizing Objective Physical Activity Measures in Middle-Aged Females with Low-Back Pain. The Korean Journal of Measurement and Evaluation in Physical Education and Sport Science 2013;15(2):29-39. https://doi.org/10.21797/ksme.2013.15.2.003
- Devlin N, Roudijk B, Ludwig K. Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide. Cham (CH): Springer; 2022, p. 1-12.
- Park JI, Kim YJ, Cho MJ. Factor Structure of the 12-Item General Health Questionnaire in the Korean General Adult Population. J Korean Neuropsychiatr Assoc 2012;51(4):178-84. https://doi.org/10.4306/jknpa.2012.51.4.178
- Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals (Basel) 2021;14(8):807.
- Doane JJ, Hirsch KS, Baldwin JO, Wurfel MM, Pipavath SN, West TE. Progressive Pulmonary Fibrosis After Non-Critical COVID-19: A Case Report. Am J Case Rep 2021;22:e933458.
- Rai DK, Sharma P, Kumar R. Post covid 19 pulmonary fibrosis. Is it real threat? Indian J Tuberc 2021;68(3):330-3. https://doi.org/10.1016/j.ijtb.2020.11.003
- Hirawat R, Jain N, Aslam Saifi M, Rachamalla M, Godugu C. Lung fibrosis: Post-COVID-19 complications and evidences. Int Immunopharmacol 2023;116:109418.
- Zou JN, Sun L, Wang BR, Zou Y, Xu S, Ding YJ, et al. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLoS One 2021;16(3):e0248957.
- Gulati A, Lakhani P. Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series. Clin Imaging 2021;77:180-6. https://doi.org/10.1016/j.clinimag.2021.03.030
- Lazar M, Barbu EC, Chitu CE, Tiliscan C, Stratan L, Arama SS, et al. Interstitial Lung Fibrosis Following COVID-19 Pneumonia. Diagnostics (Basel) 2022;12(8):2028.
- 전국한의과대학 폐계내과학교실. 肺系內科學. 서울: 도서출판 나도; 2019, p. 464.
- Lee KY, Jeong SH, Jeong MJ, Choi YM, Song MD, Jang IS. Review on Herbal Medicine Treatment for Late Complications of COVID-19 Patients. J Int Korean Med 2021;42(1):53-66. https://doi.org/10.22246/jikm.2021.42.1.53
- Ryu NH, Park SM, Kang H, Shim BS, Kim SH, Choi SH, et al. Effect of Samsoeum on Cytokine Regulation of Mouse T cell. Korean journal of oriental physiology & pathology 2008;22(4):856-62.
- Lyu Y, Kim KI, Yang CS, Jung SY, Kwon O, Jung HJ, et al. Efficacy and Safety of Ojeok-San Plus Saengmaek-San for Gastroesophageal Reflux-Induced Chronic Cough: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers in Pharmacology 2022;13:787860.
- 남산당편집국. 對譯 證脈,方藥合編. 서울: 남산당; 2003, p. 136-7.
- Kim JH, Lee DH, Kim JH, Jung SE, Ham SH, Yang WM, et al. Anti-inflammatory Effects of Ojeok-san in LPS-induced Inflammatory Rat Model. J Korean Med 2021;42(2):21-30. https://doi.org/10.13048/jkm.21012
- Shin IS, Lee MY, Jeon WY, Kim JC, Shin HK. Ojeok-san, a Traditional Korean Herbal Medicine Attenuates Airway Inflammation and Pulmonary Fibrosis Induced by Repeated Ovalbumin challenge. J Ethnopharmacol 2013;149(1):281-7. https://doi.org/10.1016/j.jep.2013.06.036
- Ji K, Ma J, Wang L, Li N, Dong S, Shi L. Efficacy and safety of traditional Chinese medicine in idiopathic pulmonary fibrosis: a meta-analysis. Evidence-Based Complementary and Alternative Medicine 2020;2020:1-11. https://doi.org/10.1155/2020/1752387
- Li F, Lv YN, Tan YS, Shen K, Zhai KF, Chen HL, et al. An integrated pathway interaction network for the combination of four effective compounds from ShengMai preparations in the treatment of cardio-cerebral ischemic diseases. Acta Pharmacologica Sinica 2015;36(11):1337-48. https://doi.org/10.1038/aps.2015.70
- Jang SB, Kim DS, Yi EH, Choi GH, Son MD, Lee EK, et al. Telemedicine and the Use of Korean Medicine for Patients With COVID-19 in South Korea: Observational Study. JMIR Public Health and Surveillance 2021;7(1):e20236.
- Chiang SC, Park J, Bae J, Joo H, Lee D, Kim KI, et al. Antifibrotic effects of lilii bulbus extract in a mouse model of bleomycin-induced pulmonary fibrosis. Pharmacognosy Magazine 2021;17(76):679-83. https://doi.org/10.4103/pm.pm_117_21
- Liu WH, Guo SN, Fang W, Yang H. Understanding of guidance for acupuncture and moxibustion interventions on COVID-19 issued by CAAM. World journal of acupuncture-moxibustion 2020;30(1):1-4. https://doi.org/10.1016/j.wjam.2020.03.005
- 침구경혈학교실. 침구학. 서울: 집문당; 1988.
- Li B, Zhang Y, Yang QM. Umbilical moxibustion for patients with idiopathic pulmonary fibrosis complicated with gastroesophageal reflux of lung-spleen qi deficiency. Chinese Acupuncture & Moxibustion 2019;39(3):241-5..
- Cheng L, Li R, Zhou M, Li F, Chang Q, Li C, et al. Moxibustion has a positive effect on pulmonary fibrosis:an alternative approach. Afr J Tradit Complement Altern Med 2017;14(2):125-9. https://doi.org/10.21010/ajtcam.v14i2.13
- Lechowicz K, Drozdzal S, Machaj F, Rosik J, Szostak B, Zegan-Baranska M, et al. COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. J Clin Med 2020;9(6):1917.